BioNTech (NASDAQ:BNTX) Research Coverage Started at Citigroup

Citigroup initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $145.00 price target on the stock.

A number of other analysts also recently issued reports on BNTX. BMO Capital Markets raised their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Wells Fargo & Company initiated coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. Morgan Stanley decreased their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Finally, Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Stock Performance

Shares of BNTX stock opened at $99.47 on Thursday. The firm has a 50-day moving average of $115.49 and a 200-day moving average of $113.19. The company has a market cap of $23.85 billion, a P/E ratio of -47.37 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.90 earnings per share. Equities research analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently modified their holdings of the company. Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after acquiring an additional 128 shares during the period. Bank of New York Mellon Corp boosted its position in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares during the period. Probity Advisors Inc. boosted its position in shares of BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after acquiring an additional 154 shares during the period. Midwest Professional Planners LTD. boosted its position in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after acquiring an additional 222 shares during the period. Finally, Perigon Wealth Management LLC boosted its position in shares of BioNTech by 3.9% in the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after acquiring an additional 224 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.